| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 3 | 2020 | 131 | 1.640 |
Why?
|
| Cell Culture Techniques | 2 | 2020 | 7 | 1.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2024 | 6 | 1.140 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 9 | 1.130 |
Why?
|
| Models, Biological | 3 | 2020 | 77 | 1.120 |
Why?
|
| Biomarkers, Tumor | 4 | 2024 | 25 | 1.070 |
Why?
|
| Proteome | 1 | 2020 | 5 | 0.720 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 13 | 0.720 |
Why?
|
| Lymph Nodes | 1 | 2020 | 13 | 0.710 |
Why?
|
| Inflammation | 1 | 2020 | 104 | 0.690 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 198 | 0.650 |
Why?
|
| Hypertension | 15 | 2012 | 419 | 0.610 |
Why?
|
| Killer Cells, Natural | 2 | 2024 | 52 | 0.550 |
Why?
|
| Humans | 46 | 2024 | 14537 | 0.520 |
Why?
|
| Female | 36 | 2024 | 9103 | 0.510 |
Why?
|
| Cell Communication | 1 | 2015 | 3 | 0.510 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 7 | 0.500 |
Why?
|
| Middle Aged | 29 | 2024 | 3601 | 0.420 |
Why?
|
| Amino Acid Transport Systems | 1 | 2011 | 2 | 0.390 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2011 | 3 | 0.390 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 4 | 0.390 |
Why?
|
| Arginine | 1 | 2011 | 5 | 0.390 |
Why?
|
| Male | 35 | 2024 | 6754 | 0.380 |
Why?
|
| Cardiomyopathy, Dilated | 6 | 2002 | 35 | 0.380 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 9 | 2006 | 29 | 0.370 |
Why?
|
| Blood Pressure | 14 | 2015 | 317 | 0.350 |
Why?
|
| Aged | 12 | 2024 | 1740 | 0.350 |
Why?
|
| Polymorphism, Genetic | 5 | 2002 | 99 | 0.350 |
Why?
|
| Ventricular Function, Left | 9 | 2004 | 80 | 0.350 |
Why?
|
| Cicatrix, Hypertrophic | 1 | 2008 | 1 | 0.320 |
Why?
|
| Surgical Tape | 1 | 2008 | 1 | 0.320 |
Why?
|
| Postoperative Care | 1 | 2008 | 2 | 0.320 |
Why?
|
| Bandages | 1 | 2008 | 21 | 0.320 |
Why?
|
| MCF-7 Cells | 2 | 2020 | 6 | 0.310 |
Why?
|
| Prospective Studies | 17 | 2020 | 1160 | 0.300 |
Why?
|
| Drainage | 1 | 2008 | 2 | 0.300 |
Why?
|
| Anesthetics, Local | 1 | 2008 | 6 | 0.300 |
Why?
|
| Amides | 1 | 2008 | 8 | 0.300 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 6 | 0.300 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 26 | 0.290 |
Why?
|
| Antihypertensive Agents | 6 | 2012 | 64 | 0.290 |
Why?
|
| Pentoxifylline | 6 | 2004 | 13 | 0.290 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 468 | 0.260 |
Why?
|
| Stroke Volume | 6 | 2015 | 43 | 0.260 |
Why?
|
| Case-Control Studies | 5 | 2020 | 480 | 0.250 |
Why?
|
| Disease Progression | 1 | 2024 | 154 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 20 | 0.220 |
Why?
|
| Appendicitis | 1 | 2022 | 2 | 0.200 |
Why?
|
| Appendix | 1 | 2022 | 3 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 370 | 0.200 |
Why?
|
| Adult | 17 | 2024 | 5913 | 0.200 |
Why?
|
| Hydrochlorothiazide | 5 | 2002 | 9 | 0.200 |
Why?
|
| South Africa | 15 | 2024 | 7596 | 0.190 |
Why?
|
| Heart Ventricles | 4 | 2004 | 60 | 0.190 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2003 | 12 | 0.190 |
Why?
|
| Systole | 3 | 2004 | 37 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2020 | 5 | 0.180 |
Why?
|
| Cell Shape | 1 | 2020 | 3 | 0.180 |
Why?
|
| Prognosis | 2 | 2020 | 199 | 0.180 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 6 | 0.180 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 7 | 0.180 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 20 | 0.180 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 22 | 0.180 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 41 | 0.180 |
Why?
|
| Biopsy, Needle | 1 | 2020 | 4 | 0.180 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 2 | 0.180 |
Why?
|
| Axilla | 1 | 2020 | 3 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2020 | 967 | 0.180 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 9 | 0.180 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 14 | 0.180 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 14 | 0.180 |
Why?
|
| Calcium Channel Blockers | 5 | 2006 | 14 | 0.170 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 1 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2000 | 5 | 0.170 |
Why?
|
| Signal Transduction | 1 | 2020 | 33 | 0.170 |
Why?
|
| Paresis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Interleukins | 1 | 2019 | 3 | 0.160 |
Why?
|
| Pancreatitis | 1 | 2019 | 8 | 0.160 |
Why?
|
| Time Factors | 7 | 2019 | 507 | 0.160 |
Why?
|
| Regression Analysis | 4 | 2011 | 133 | 0.160 |
Why?
|
| Gene Expression | 1 | 2019 | 43 | 0.160 |
Why?
|
| Cardiomyopathies | 3 | 2004 | 15 | 0.150 |
Why?
|
| Animals | 8 | 2020 | 1081 | 0.150 |
Why?
|
| Kidney | 2 | 1996 | 46 | 0.150 |
Why?
|
| Carbazoles | 3 | 2004 | 5 | 0.150 |
Why?
|
| Propanolamines | 3 | 2004 | 8 | 0.150 |
Why?
|
| Angiotensinogen | 4 | 2006 | 15 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 1 | 0.140 |
Why?
|
| Laparotomy | 1 | 2017 | 2 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2017 | 4 | 0.140 |
Why?
|
| Intestinal Mucosa | 1 | 2017 | 9 | 0.140 |
Why?
|
| Intestinal Perforation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 8 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2017 | 34 | 0.140 |
Why?
|
| Phenotype | 3 | 2015 | 158 | 0.140 |
Why?
|
| Echocardiography | 7 | 2015 | 100 | 0.140 |
Why?
|
| Mining | 2 | 2007 | 41 | 0.130 |
Why?
|
| Giraffes | 1 | 2015 | 1 | 0.130 |
Why?
|
| Ventricular Function | 1 | 2015 | 1 | 0.130 |
Why?
|
| Cardiac Output | 1 | 2015 | 4 | 0.130 |
Why?
|
| fas Receptor | 5 | 2004 | 13 | 0.130 |
Why?
|
| Mucin-1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Endopeptidase K | 1 | 2015 | 1 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 1 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2002 | 47 | 0.130 |
Why?
|
| ErbB Receptors | 1 | 2015 | 14 | 0.130 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 14 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 9 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2004 | 44 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2015 | 67 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 12 | 0.120 |
Why?
|
| Cystatin C | 1 | 2015 | 9 | 0.120 |
Why?
|
| Diuretics | 6 | 2005 | 16 | 0.120 |
Why?
|
| Creatinine | 1 | 2015 | 53 | 0.120 |
Why?
|
| Genotype | 6 | 2006 | 442 | 0.120 |
Why?
|
| Diastole | 6 | 2004 | 43 | 0.120 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 5 | 2012 | 27 | 0.110 |
Why?
|
| Heart Failure | 2 | 2004 | 38 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2004 | 65 | 0.110 |
Why?
|
| Treatment Outcome | 10 | 2012 | 889 | 0.110 |
Why?
|
| Indapamide | 2 | 2004 | 4 | 0.110 |
Why?
|
| Puerperal Disorders | 2 | 2004 | 9 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 2 | 2004 | 23 | 0.110 |
Why?
|
| Cytochrome P-450 CYP11B2 | 2 | 2003 | 5 | 0.110 |
Why?
|
| Enuresis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Renin-Angiotensin System | 2 | 2003 | 12 | 0.100 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 16 | 0.100 |
Why?
|
| Parents | 1 | 2012 | 32 | 0.100 |
Why?
|
| Enalapril | 3 | 2002 | 7 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 472 | 0.100 |
Why?
|
| Ethylmaleimide | 1 | 2011 | 2 | 0.100 |
Why?
|
| Nonlinear Dynamics | 1 | 2011 | 3 | 0.100 |
Why?
|
| Leucine | 1 | 2011 | 4 | 0.100 |
Why?
|
| Carboxylic Acids | 1 | 2011 | 3 | 0.100 |
Why?
|
| Kinetics | 1 | 2011 | 65 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2011 | 79 | 0.100 |
Why?
|
| Vasodilator Agents | 3 | 2001 | 11 | 0.100 |
Why?
|
| Sodium | 1 | 2011 | 30 | 0.100 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 44 | 0.090 |
Why?
|
| Algorithms | 1 | 2011 | 106 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 3 | 2015 | 62 | 0.090 |
Why?
|
| Cytokines | 2 | 2002 | 107 | 0.090 |
Why?
|
| Risk Factors | 4 | 2012 | 1475 | 0.090 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 253 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 25 | 0.080 |
Why?
|
| Popliteal Artery | 1 | 2008 | 4 | 0.080 |
Why?
|
| Gels | 1 | 2008 | 19 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2008 | 14 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 37 | 0.080 |
Why?
|
| Myocardium | 2 | 1999 | 35 | 0.080 |
Why?
|
| Abdominal Wall | 1 | 2008 | 5 | 0.070 |
Why?
|
| Suture Techniques | 1 | 2007 | 6 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2007 | 6 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2007 | 8 | 0.070 |
Why?
|
| Young Adult | 2 | 2019 | 2498 | 0.070 |
Why?
|
| Lung Diseases, Fungal | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cryptococcosis | 1 | 2007 | 17 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2004 | 9 | 0.070 |
Why?
|
| Pneumocystis carinii | 1 | 2006 | 9 | 0.070 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2006 | 16 | 0.070 |
Why?
|
| Double-Blind Method | 6 | 2004 | 272 | 0.070 |
Why?
|
| Renal Circulation | 2 | 1996 | 5 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 4 | 0.060 |
Why?
|
| Cardiomegaly | 1 | 2005 | 8 | 0.060 |
Why?
|
| Pneumonia | 1 | 2007 | 131 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 22 | 0.060 |
Why?
|
| Adolescent | 3 | 2008 | 2985 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2022 | 799 | 0.060 |
Why?
|
| Verapamil | 2 | 2002 | 4 | 0.060 |
Why?
|
| Nifedipine | 2 | 2002 | 5 | 0.060 |
Why?
|
| Digoxin | 2 | 2002 | 6 | 0.060 |
Why?
|
| Pancreatitis, Chronic | 1 | 2024 | 4 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 23 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2024 | 24 | 0.060 |
Why?
|
| Amlodipine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Perindopril | 1 | 2004 | 4 | 0.060 |
Why?
|
| Body Mass Index | 4 | 2012 | 321 | 0.060 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 2 | 2001 | 4 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2004 | 12 | 0.060 |
Why?
|
| Drug Therapy, Combination | 5 | 2005 | 279 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2004 | 31 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 34 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 117 | 0.050 |
Why?
|
| Prevalence | 3 | 2012 | 1192 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2002 | 133 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 36 | 0.050 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 1 | 2002 | 2 | 0.050 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2002 | 3 | 0.050 |
Why?
|
| Gated Blood-Pool Imaging | 2 | 1999 | 3 | 0.050 |
Why?
|
| Appendectomy | 1 | 2022 | 3 | 0.050 |
Why?
|
| Survival Rate | 2 | 2000 | 96 | 0.050 |
Why?
|
| Technetium Tc 99m Pentetate | 3 | 1998 | 5 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 103 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2000 | 10 | 0.050 |
Why?
|
| Collagen | 2 | 1997 | 23 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2020 | 3 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 2 | 0.040 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2000 | 1 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 7 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2000 | 3 | 0.040 |
Why?
|
| Papio | 2 | 1998 | 28 | 0.040 |
Why?
|
| Apolipoprotein A-I | 1 | 2000 | 3 | 0.040 |
Why?
|
| Vasodilation | 1 | 2000 | 7 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 10 | 0.040 |
Why?
|
| DNA Primers | 1 | 2000 | 55 | 0.040 |
Why?
|
| Isoproterenol | 1 | 2000 | 20 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2000 | 25 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 46 | 0.040 |
Why?
|
| Base Sequence | 1 | 2000 | 149 | 0.040 |
Why?
|
| Acebutolol | 1 | 1999 | 1 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2000 | 85 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 74 | 0.040 |
Why?
|
| Cardiac Output, Low | 1 | 1999 | 3 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 1999 | 8 | 0.040 |
Why?
|
| Genetic Markers | 1 | 1999 | 11 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 20 | 0.040 |
Why?
|
| Nisoldipine | 1 | 1999 | 1 | 0.040 |
Why?
|
| Gene Deletion | 1 | 1999 | 19 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 1422 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 105 | 0.040 |
Why?
|
| HIV Infections | 2 | 2015 | 5097 | 0.040 |
Why?
|
| Alleles | 1 | 1999 | 143 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 150 | 0.040 |
Why?
|
| Primate Diseases | 1 | 1998 | 2 | 0.040 |
Why?
|
| Ureteral Obstruction | 1 | 1998 | 3 | 0.040 |
Why?
|
| Radioisotope Renography | 1 | 1998 | 3 | 0.040 |
Why?
|
| Sepsis | 1 | 2019 | 102 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 1997 | 33 | 0.040 |
Why?
|
| Rabbits | 1 | 2017 | 35 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1996 | 6 | 0.030 |
Why?
|
| Guanidines | 1 | 1996 | 8 | 0.030 |
Why?
|
| Autopsy | 2 | 2007 | 140 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 29 | 0.030 |
Why?
|
| Kidney Cortex | 1 | 1994 | 1 | 0.030 |
Why?
|
| Nephrons | 1 | 1994 | 2 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1994 | 4 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 1994 | 2 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2004 | 7 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 2 | 2004 | 18 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 1994 | 38 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2004 | 37 | 0.030 |
Why?
|
| Renin | 2 | 2006 | 10 | 0.030 |
Why?
|
| Aldosterone | 2 | 2006 | 12 | 0.030 |
Why?
|
| Aging | 1 | 1994 | 109 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 125 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2002 | 38 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2002 | 156 | 0.030 |
Why?
|
| Heart Rate | 2 | 2004 | 32 | 0.020 |
Why?
|
| Logistic Models | 2 | 2002 | 254 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2002 | 179 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 563 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2008 | 5 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 19 | 0.020 |
Why?
|
| Biomarkers | 2 | 2000 | 327 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 188 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2007 | 3 | 0.020 |
Why?
|
| Constriction | 1 | 2007 | 6 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2007 | 11 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 8 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1748 | 0.020 |
Why?
|
| Pregnancy | 2 | 2004 | 1862 | 0.020 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2007 | 16 | 0.020 |
Why?
|
| Captopril | 2 | 1997 | 5 | 0.020 |
Why?
|
| Organ Size | 2 | 1997 | 34 | 0.020 |
Why?
|
| Rats | 2 | 1997 | 130 | 0.020 |
Why?
|
| Child | 1 | 2012 | 2242 | 0.020 |
Why?
|
| Remission Induction | 1 | 2005 | 6 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2004 | 7 | 0.010 |
Why?
|
| Exercise Test | 1 | 2004 | 13 | 0.010 |
Why?
|
| Outpatients | 1 | 2003 | 38 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 77 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 96 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2002 | 9 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 8 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2002 | 32 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 2002 | 2 | 0.010 |
Why?
|
| Furosemide | 1 | 2002 | 3 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 27 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 8 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 64 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2002 | 27 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2002 | 40 | 0.010 |
Why?
|
| Methyldopa | 1 | 2002 | 2 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 176 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 2001 | 4 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2002 | 120 | 0.010 |
Why?
|
| Africa | 1 | 2002 | 376 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2001 | 163 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 40 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 127 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1999 | 2 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 1999 | 18 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 367 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1999 | 68 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 64 | 0.010 |
Why?
|
| Hydralazine | 1 | 1997 | 3 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 1997 | 17 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 1997 | 17 | 0.010 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1997 | 5 | 0.010 |
Why?
|
| Solubility | 1 | 1997 | 51 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1997 | 45 | 0.010 |
Why?
|
| Hippurates | 1 | 1996 | 2 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 3 | 0.010 |
Why?
|
| Hematocrit | 1 | 1996 | 6 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 8 | 0.010 |
Why?
|
| Body Weight | 1 | 1997 | 111 | 0.010 |
Why?
|
| Streptozocin | 1 | 1996 | 2 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1996 | 63 | 0.010 |
Why?
|